Stevanato Group Spa Dossier - Source-backed chat

Stevanato Group Spa

STVNNYSE

SectorHealth Care

IndustryMedical Instruments & Supplies

Beta (adjusted)0.82

Intrinsic Value $21.96median of 6 methods · middle span $15-$28based on filings through 31 Dec 2025

Market Price $19.98Price as of 1 Oct 2026

Near fair valueIntrinsic value is 10% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $5.5B

Enterprise Value $5.8B

Shares Outstanding 273.1M diluted

Moat Rating Narrow

Next Earnings Date5 Nov 2026

Last ex-dividend11 Jun 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Stevanato Group S.p.A. (STVN) represents a high-conviction secular growth story within the biopharmaceutical supply chain, transitioning from a capital-intensive buildout phase to a highly visible execution and margin-expansion phase. The company is uniquely positioned to benefit from the explosive demand for GLP-1/incretin-based therapies, biologics, and premium containment solutions. While near-term free cash flow has been temporarily weighed down by heavy capital expenditures at its new Latina (Italy) and Fishers (US) facilities, these investments establish structurally higher future earnings power. The market's excessive skepticism regarding near-term ramp costs and temporary engineering segment weakness undervalues Stevanato's improving product mix, expanding margins, and long-term compounding potential.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets11 analysts · as of 18 Aug 2026

Low · most bearish analyst$20.00

Mean target$24.74

High · most bullish analyst$32.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$20.00

Prolonged operational inefficiencies and higher-than-expected depreciation drag at the new manufacturing plants continue to compress gross margins. The Engineering segment's low backlog and slow order intake lead to deeper revenue declines, while a potential shift toward oral GLP-1 alternatives or rising competitive pressures from Schott Pharma and Gerresheimer limits high-value syringe pricing power.

Base CaseCentral scenario

$24.74

Matches the consensus mean

Stevanato successfully executes its fiscal 2026 guidance, delivering revenue between €1.26 billion and €1.29 billion and adjusted diluted EPS of €0.59 to €0.63. High-value solutions steadily grow to represent 47% to 48% of total revenue, supported by mid-teens growth in GLP-1 volumes. The Engineering segment stabilizes under the ongoing business optimization plan, and capital expenditure begins to moderate, leading to a gradual re-rating of the stock toward historical multiples.

Bull CaseUpside scenario

$32.00

Accelerated commercialization of the newly launched Deora™ pen injector platform and faster-than-expected capacity ramp-up at the Fishers and Latina facilities drive high-value solutions (HVS) to exceed 50% of total revenue. Strong operating leverage and a rapid recovery in the Engineering segment lead to significant margin expansion, pushing adjusted EBITDA margins toward 30% and generating substantial positive free cash flow ahead of schedule.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Pure-play exposure to high-growth biopharma trends, particularly GLP-1/incretin therapies and biologics.
Proprietary technology portfolio, including the newly launched Deora™ multi-use pen injector platform and established Alina® and Aidaptus® systems.
Favorable product mix shift toward high-margin High-Value Solutions (HVS), which carry significantly higher profitability.
Unique competitive advantage from its Engineering segment, allowing in-house design and optimization of glass converting and visual inspection machinery.

Key Investment Risks

Near-term margin pressure from start-up inefficiencies, ramp costs, and elevated depreciation at the Latina and Fishers facilities.
Continued cyclical weakness and low order backlog in the Engineering segment.
Foreign exchange headwinds, particularly from the Euro-Dollar exchange rate, impacting reported figures.
Long-term risk of therapeutic shifts from injectable drug delivery to oral alternatives.

Thesis Invalidation Triggers

Adjusted EBITDA margin falling below 22% due to persistent operational inefficiencies.
A material loss of market share in the GLP-1 containment or device supply chain to key competitors.
Significant delays or structural cost overruns in achieving full commercial production at the Fishers, Indiana facility.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.